Skip to content
Login Register

#insulin production

8 public questions tagged with this topic.

Gene Therapy

Cyanogen bromide is used in insulin production to:

Cyanogen bromide chemical cleavage exquisite selectivity methionine residues enabling precise excision fusion partner. Mechanism involves nucleophilic attack thioether sulfur methionine electrophilic carbon CNBr generating cyanosulfonium intermediate undergoing intramolecular cyclization carbonyl oxygen forming iminolactone ring subsequently hydrolyzed acidic conditions homoserine lactone C-terminal cleavage site while N-terminal fragment released. Specificity exploited recombinant insulin manufacturing where fusion proteins engineered single methionine codon junction between beta-galactosidase carrier and insulin A or B chain, while insulin sequences devoid internal methionine due codon optimization avoiding ATG inside coding preserving integrity upon CNBr treatment. Reaction performed tenfold molar excess CNBr 70 percent formic acid 20-24h room temperature dark quantitatively liberating insulin chains retaining S-sulfonated cysteines protecting thiols random oxidation. Cleavage efficiency >90 percent, but side reactions oxidation tyrosine dibromotyrosine cleavage tryptophan strong conditions modification serine requiring careful control pH temperature. Modern mammalian production favors enzymatic cleavage trypsin carboxypeptidase B avoiding toxic chemical reagents improving specificity environmentally friendly process.

Ref: Methods Enzymol Cyanogen Bromide Cleavage Meinke 1981; Watson Molecular Biology Protein Cleavage Methods; NCERT Biotechnology Bioprocess Cleavage Techniques.

View Details
Gene Therapy

Recombinant insulin production involves fusion with:

Early industrial production human insulin 1982 relied fusion protein technology because small 51 aa insulin A 21 B 30 rapidly degraded bacterial cytoplasm proteases Lon Clp if expressed mature alone. Genentech team Riggs Boyer Goeddel chemically synthesized DNA encoding insulin chains separately fused carboxy terminus E. coli beta-galactosidase 1024 aa enzyme encoded lacZ or trp leader peptide. Large fusion drove formation insoluble inclusion bodies protecting heterologous peptide from proteolysis enabling purification centrifugation detergent washes. Construct single methionine codon junction providing CNBr cleavage site. After solubilization formic acid cleavage S-sulfonated A B chains purified gel filtration ion exchange mixed equimolar ratio oxidative conditions reduced oxidized glutathione facilitating correct disulfide bonds A6-A11 intrachain A7-B7 A20-B19 interchain yielding biologically active insulin identical human pancreatic hormone lacking immunogenic contaminants bovine insulin. Product entered market Humulin first recombinant pharmaceutical approved FDA October 1982, pioneering biotech industry demonstrating recombinant protein production commercial viability subsequently adapted for growth hormone.

Ref: Science History Institute Recombinant Insulin LacZ Fusion 1982; NCBI Bookshelf Insulin Fusion Production; Goeddel et al PNAS 1979 Insulin Expression.

View Details